Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4475 AUD | -2.72% | -1.65% | +29.71% |
17/05 | Capital One Initiates Immutep at Overweight Rating With $10 Price Target | MT |
15/05 | Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.71% | 37Cr | |
+64.92% | 6.26TCr | |
-1.85% | 4.12TCr | |
+44.76% | 4.03TCr | |
-8.93% | 2.79TCr | |
+13.05% | 2.62TCr | |
-21.96% | 1.91TCr | |
+4.21% | 1.31TCr | |
+25.74% | 1.23TCr | |
+27.42% | 1.21TCr |
- Stock Market
- Equities
- IMM Stock
- News Immutep Limited
- Immutep Says US FDA Awarded Fast Track Designation for Proposed Treatment of First-Line Non-Small Cell Lung Cancer